Journal article
Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
- Abstract:
-
he annual incidence of pneumonia has been reported as 13.8/1000 in patients with IBD versus 7.6/1000 in healthy subjects (IRR 1.82; 95% CI: 1.75–1.88) [1]. Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin, selectively blocking gut-specific lymphocyte trafficking. Gut selectivity may reduce the infection risk compared with anti-tumour necrosis factor-alpha [anti-TNFα] agents, which cause systemic immunosuppression. Here we describe pneumonia and other respirator...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 325.4KB)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjx002.792
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- Journal of Crohn's and Colitis Journal website
- Volume:
- 11
- Issue:
- S1
- Pages:
- S421–S422
- Publication date:
- 2017-02-01
- Acceptance date:
- 2016-12-15
- DOI:
- ISSN:
-
1873-9946
- Pmid:
-
28172558
- Source identifiers:
-
719788
Item Description
- Pubs id:
-
pubs:719788
- UUID:
-
uuid:d86dbdcc-3b70-4aee-aae4-2c127c727be0
- Local pid:
- pubs:719788
- Deposit date:
- 2017-08-25
Terms of use
- Copyright holder:
- European Crohn’s and Colitis Organisation
- Copyright date:
- 2017
- Notes:
- © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from OUP at: 10.1093/ecco-jcc/jjx002.792. This poster was presented at the 12th Congress of ECCO (February 15-18, 2017: Barcelona, Spain).
If you are the owner of this record, you can report an update to it here: Report update to this record